When a radiology report lists 'multiple bilateral pulmonary nodules' along with a number, families almost always arrive at the same question: can't each one be taken out? In the clinic, however, the first dividing line is not how many spots there are, but how the disease is behaving overall. This article explains that reasoning in general terms.
Cancer cells most often reach the lungs through the bloodstream. Because venous blood from the entire body passes through the lungs, the lungs act as an early filter for circulating cells. So when nodules appear in both lungs and in scattered locations, clinicians read that pattern as evidence that cancer cells are present in the circulation, not only in the visible spots. Even if every visible nodule were removed, lesions too small to appear on imaging would likely remain. That is why systemic therapy, such as chemotherapy or targeted therapy, is the backbone of treatment for widespread metastases.
Local treatment is still considered in some situations. The term oligometastasis describes a state in which the number of metastases is limited, the lesions are reachable, disease elsewhere is controlled, and new lesions are not continuously appearing over a period of observation. In that setting, stereotactic body radiotherapy (SBRT), thoracoscopic wedge resection, or radiofrequency ablation (RFA) may be discussed. When dozens of nodules are spread through both lungs and continue to increase during treatment, the potential benefit of local treatment narrows while the costs, including loss of lung capacity and recovery time, remain. The answer to 'why not remove them one by one' is usually about this balance, not about a lack of technique.
Counting also matters less than people expect when judging response. Nodules under one centimeter may be counted differently depending on imaging conditions and the reading radiologist, and they can be hard to distinguish from inflammation or scarring. In practice, a few measurable lesions are chosen as targets and followed for size change, alongside overall disease burden, symptoms, weight, performance status, laboratory values, and tumor marker trends. A slightly higher count alone is not treated as proof of failure, and a stable count with growing lesions can still indicate progression.
When a treatment line is changing, several things are worth confirming. First, biomarkers: in colorectal cancer, RAS and BRAF mutations, microsatellite instability (MSI-H/dMMR), and HER2 amplification can change which drugs are available, so it is reasonable to ask whether tissue or blood-based testing has been done. Second, clinical trials: as standard options narrow, trials may become a practical alternative, and the care team can advise whether any are open and whether referral is needed. Third, symptom control and physical condition, since being well enough to receive the next treatment is itself what keeps options open.
The wish to try anything is a natural response to a long illness. That urgency, however, also makes people vulnerable to expensive unproven procedures and supplements. Before starting anything new, it is safer to ask the treating team about interactions with current drugs, liver and kidney burden, and effects on the treatment schedule. Bringing specific questions, such as whether the goal is shrinking or controlling disease, when and how response will be assessed, and whether local treatment could ever be considered, helps make short appointments more useful.
This article provides general medical information and does not replace individual diagnosis or treatment. Decisions depend heavily on stage, genomic testing, prior response, and organ function, so please discuss your specific situation with your medical team.